Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

Swedish (OMX) Biotech Industry Analysis

UpdatedJan 10, 2026
DataAggregated Company Financials
Companies50
  • 7D4.6%
  • 3M7.4%
  • 1Y-0.9%
  • YTD4.6%

In the last week, the Biotech industry is up 3.4%, with Swedish Orphan Biovitrum up 5.3%. Despite this gain, the industry's performance has been flat over the past year. Looking forward, earnings are forecast to grow by 30% annually.

Industry Valuation and Performance

Has the Swedish Biotech Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Sat, 10 Jan 2026SEK 215.2bSEK 38.1b-SEK 556,297,658.1836x-386.9x5.7x
Mon, 08 Dec 2025SEK 209.4bSEK 38.1b-SEK 603,799,286.9831.5x-346.9x5.5x
Wed, 05 Nov 2025SEK 205.7bSEK 37.3b-SEK 1,210,403,737.1138.2x-170x5.5x
Fri, 03 Oct 2025SEK 208.1bSEK 36.4bSEK 3.0b31.4x68.8x5.7x
Sun, 31 Aug 2025SEK 200.9bSEK 36.4bSEK 3.0b31.1x66.6x5.5x
Tue, 29 Jul 2025SEK 192.7bSEK 35.9bSEK 2.8b28.6x69.1x5.4x
Thu, 26 Jun 2025SEK 179.6bSEK 35.2bSEK 2.2b28x80.7x5.1x
Sat, 24 May 2025SEK 185.8bSEK 35.2bSEK 2.2b29.4x83.1x5.3x
Mon, 21 Apr 2025SEK 175.2bSEK 33.7bSEK 758.0m29x231.2x5.2x
Wed, 19 Mar 2025SEK 193.0bSEK 33.7bSEK 579.5m33.7x333.1x5.7x
Fri, 14 Feb 2025SEK 217.8bSEK 33.8bSEK 347.9m54.2x626.1x6.5x
Sun, 12 Jan 2025SEK 215.7bSEK 33.0b-SEK 4,418,472,612.01154.7x-48.8x6.5x
Tue, 10 Dec 2024SEK 212.8bSEK 33.0b-SEK 4,445,654,523.81143.3x-47.9x6.4x
Thu, 07 Nov 2024SEK 215.0bSEK 33.2b-SEK 4,478,456,953.44140.1x-48x6.5x
Sat, 05 Oct 2024SEK 207.5bSEK 31.4b-SEK 5,524,008,836.2648.6x-37.6x6.6x
Mon, 02 Sep 2024SEK 216.4bSEK 31.5b-SEK 5,518,037,354.7351.1x-39.2x6.9x
Wed, 31 Jul 2024SEK 197.8bSEK 31.4b-SEK 5,421,530,700.5443.7x-36.5x6.3x
Fri, 28 Jun 2024SEK 196.2bSEK 30.6b-SEK 5,398,410,255.8439.4x-36.3x6.4x
Sun, 26 May 2024SEK 193.4bSEK 30.6b-SEK 5,406,535,340.1039.4x-35.8x6.3x
Tue, 23 Apr 2024SEK 178.5bSEK 29.8b-SEK 5,265,765,392.2366.1x-33.9x6x
Thu, 21 Mar 2024SEK 184.7bSEK 29.8b-SEK 5,637,388,054.1657.7x-32.8x6.2x
Sat, 17 Feb 2024SEK 177.3bSEK 29.7b-SEK 5,668,408,815.3654x-31.3x6x
Mon, 15 Jan 2024SEK 190.3bSEK 28.7b-SEK 1,198,820,921.0060.5x-158.8x6.6x
Wed, 13 Dec 2023SEK 168.5bSEK 28.7b-SEK 1,200,358,818.0055.7x-140.4x5.9x
Fri, 10 Nov 2023SEK 162.4bSEK 28.7b-SEK 1,294,007,859.0051.2x-125.5x5.7x
Sun, 08 Oct 2023SEK 160.1bSEK 27.4b-SEK 2,017,078,379.0048.4x-79.4x5.9x
Tue, 05 Sep 2023SEK 153.8bSEK 27.4b-SEK 1,981,479,722.0053.4x-77.6x5.6x
Thu, 03 Aug 2023SEK 156.2bSEK 27.5b-SEK 1,534,855,086.0054.2x-101.7x5.7x
Sat, 01 Jul 2023SEK 161.7bSEK 26.4b-SEK 1,317,402,647.0045x-122.8x6.1x
Mon, 29 May 2023SEK 170.8bSEK 26.3b-SEK 1,210,350,862.0046.3x-141.1x6.5x
Wed, 26 Apr 2023SEK 173.2bSEK 25.5b-SEK 2,076,039,629.0039.9x-83.4x6.8x
Fri, 24 Mar 2023SEK 166.2bSEK 25.4b-SEK 2,031,176,731.0038.7x-81.8x6.5x
Sun, 19 Feb 2023SEK 172.6bSEK 25.4b-SEK 2,100,404,946.0038.2x-82.2x6.8x
Tue, 17 Jan 2023SEK 178.1bSEK 23.8b-SEK 1,844,962,528.0033x-96.5x7.5x
Price to Earnings Ratio

-96.5x


Total Market Cap: SEK 178.1bTotal Earnings: -SEK 1,844,962,528.00Total Revenue: SEK 23.8bTotal Market Cap vs Earnings and Revenue0%0%0%
Swedish Biotech Industry Price to Earnings3Y Average -46.2x202420252026
Current Industry PE
  • Investors are relatively neutral on the Swedish Biotechs industry at the moment, indicating that they anticipate long term growth rates to remain steady.
  • The industry is trading close to its 3-year average PS ratio of 6.1x.
Past Earnings Growth
  • The earnings for companies in the Biotechs industry have improved over the last three years.
  • Revenues for these companies have grown 17% per year.
  • This means that more sales are being generated by these companies overall, and subsequently losses are decreasing too.

Industry Trends

Which industries have driven the changes within the Swedish Healthcare industry?

SE Market2.90%
Healthcare3.51%
Biotech4.61%
Biotech4.61%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
SOBI Swedish Orphan BiovitrumSEK 347.805.3%
+SEK 6.0b		11.0%PE9220.9x
BIOA B BioArcticSEK 333.007.1%
+SEK 2.0b		61.0%PE29.5x
BIOG B BioGaiaSEK 112.507.1%
+SEK 758.7m		-2.6%PE36x
BONEX Bonesupport HoldingSEK 184.803.8%
+SEK 447.8m		-51.1%PE80.1x
VICO Vicore Pharma HoldingSEK 12.4613.5%
+SEK 416.7m		30.7%PS412.6x

Latest News

CANTA
SEK 4.98
Cantargia
7D
20.8%
1Y
192.5%
BIOA B
SEK 333.00
BioArctic
7D
7.1%
1Y
61.0%

BIOA B: Future Earnings Will Depend On Risky Alzheimer Access Rollout

Analysts have maintained their fair value estimate for BioArctic at SEK 230.00. They have, however, adjusted assumptions related to the discount rate, revenue trends, profit margins, and future P/E to reflect updated views on the company’s risk profile and earnings potential.
SOBI
SEK 347.80
Swedish Orphan Biovitrum
7D
5.3%
1Y
11.0%

SOBI: Pipeline Milestones And Buy Rating Are Expected To Shape Returns

Analysts have raised their price target on Swedish Orphan Biovitrum from SEK 367.09 to about SEK 371.18, reflecting updated assumptions around discount rate, profit margin and a slightly higher future P/E, along with recent research that included an upgrade to Buy with a SEK 370 target. Analyst Commentary Bullish Takeaways Bullish analysts point to the SEK 370 price target as support for the view that the revised assumptions on discount rate, profit margin and future P/E still leave room for upside versus the previous framework.
BIOG B
SEK 112.50
BioGaia
7D
7.1%
1Y
-2.6%

BIOG B: Serotonin Link In Gut Microbiota Will Support Higher Earnings Multiple

Analysts have lifted their fair value estimate for BioGaia from SEK 130 to SEK 140, citing updated assumptions for discount rates, revenue growth, profitability and future P/E that they see as better aligned with the company’s current outlook. What's in the News Researchers linked to BioGaia reported that specific gut bacteria can produce serotonin, a key bioactive substance in the microbiota gut brain axis, with findings published in Cell Reports (Key Developments).
BONEX
SEK 184.80
Bonesupport Holding
7D
3.8%
1Y
-51.1%

BONEX: De Novo Pathway Shift Will Support Long Term Upside Potential

Analysts have kept their fair value estimate for Bonesupport Holding steady at SEK391.20, with only minor tweaks to the discount rate, revenue growth, profit margin and future P/E assumptions. This suggests their overall view on the company’s long term potential is essentially unchanged.
VICO
SEK 12.46
Vicore Pharma Holding
7D
13.5%
1Y
30.7%
HNSA
SEK 32.04
Hansa Biopharma
7D
-2.0%
1Y
-7.9%

HNSA: Buy Initiation And FDA Filing Will Shape Upside Potential

Analysts have adjusted their price view on Hansa Biopharma from SEK 143 to SEK 111, citing updated assumptions on discount rates, revenue growth, profit margins and future P/E, along with fresh coverage that includes a new SEK 100 target from Street research. Analyst Commentary Bullish analysts see the recent SEK 100 price target as a constructive marker for where Hansa Biopharma could trade if the company executes in line with their assumptions on revenue, margins and future P/E.
EGTX
SEK 4.53
Egetis Therapeutics
7D
-12.4%
1Y
-28.1%
ONCO
SEK 4.57
Oncopeptides
7D
-6.3%
1Y
193.3%

ONCO: Improved Profitability And NK Cell Platform Will Drive Long-Term Upside

Analysts have raised their price target on Oncopeptides from approximately SEK 4.50 to SEK 5.50 per share, citing expectations of stronger long term profitability, supported by higher projected profit margins and a lower future price to earnings multiple, despite slightly tempered revenue growth assumptions and a modestly higher discount rate. What's in the News Panel of leading multiple myeloma experts publishes clinical recommendations in Annals of Hematology on optimal use of Pepaxti (melflufen), reinforcing its role as an important option for relapsed, refractory multiple myeloma, including elderly and high risk patients, with a manageable safety profile (company announcement).
VITR
SEK 130.50
Vitrolife
7D
-1.9%
1Y
-37.3%

VITR: Restructuring And Goodwill Impairment Will Support Future Upside Potential

Analysts have slightly reduced their price target on Vitrolife, trimming fair value by SEK 4.75 to SEK 188.75, as modestly higher long term growth assumptions are offset by a small downgrade to profitability and a lower expected valuation multiple. What's in the News Vitrolife plans to record a SEK 5.4 billion goodwill impairment in the fourth quarter of 2025 related to the Igenomix acquisition (company announcement).
ACE
SEK 3.13
Ascelia Pharma
7D
-3.7%
1Y
4.7%
FLUO
SEK 35.00
FluoGuide
7D
-5.1%
1Y
-25.1%
DMYD B
SEK 12.60
Diamyd Medical
7D
8.4%
1Y
-26.5%
DEX
SEK 7.15
Dextech Medical
7D
-10.6%
1Y
68.6%
DVYSR
SEK 109.60
Devyser Diagnostics
7D
-3.5%
1Y
-7.5%
HAMLET B
SEK 4.20
Hamlet BioPharma
7D
14.3%
1Y
1.4%